Cardiac disorder and Galvus


Cardiac Disorder Symptoms and Causes

If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks.

Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease.

You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk:

  • Control your blood pressure
  • Lower your cholesterol
  • Don't smoke
  • Get enough exercise

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for cardiac disorder

cardiac disorder treatment research studies

Galvus clinical trials, surveys and public health registries

Find Drug Side Effect reports

Galvus Side Effects

Blood Glucose Increased (79)
Malaise (32)
Dizziness (30)
Nausea (30)
Diarrhoea (26)
Blood Pressure Increased (25)
Weight Decreased (22)
Fall (21)
Vomiting (21)
Feeling Abnormal (21)
Diabetes Mellitus Inadequate Control (19)
Fatigue (18)
Pneumonia (18)
Abdominal Pain Upper (17)
Hyperglycaemia (16)
Asthenia (14)
Headache (14)
Hypertension (14)
Hypoglycaemia (13)
Glycosylated Haemoglobin Increased (12)
Diabetes Mellitus (10)
Cerebrovascular Accident (10)
Influenza (10)
Gait Disturbance (10)
Hyperhidrosis (9)
Pain In Extremity (9)
Dyspnoea (8)
Decreased Appetite (7)
Convulsion (7)
Cardiac Disorder (7)
Infarction (7)
Death (7)
Loss Of Consciousness (7)
Pain (7)
Visual Impairment (7)
Myocardial Infarction (7)
Blood Pressure Inadequately Controlled (6)
Blood Glucose Fluctuation (6)
Abdominal Pain (6)
Blood Triglycerides Increased (6)
Blood Cholesterol Increased (6)
Tachycardia (6)
Chest Pain (6)
Cataract (6)
Tremor (6)
Urinary Tract Infection (6)
Weight Increased (6)
Blood Glucose Decreased (5)
Renal Disorder (5)
Anaemia (5)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews


After starting treating with Galvus met 50 / 500mg, my mother diabetis controlled.

Any side effects galvus 5o

Do you kow what age you have too be?

Does galvus has adverse affect? example

Does taking galvus met 500/50 be causing my feeling of not being well? This has been going on for 2 years, but it comes and goes.

Galvus is a breakthrough in antidiabetic market...

Good effects on diabetes. weight reduction -rapid and moderate to excessive hair fall after 3 months of use

Good morning ..i want ask u something,,my fother was take glucovance before 4 days and stigalptin but the dr now change to galvus met and actos,, and today he has nausea is it deal with the medication??

Good results

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

Had complete hysterectomy in 1999 and developed cystis acne. Was 34 at the time. Prescribed accutane for 9 months. Worked great with the usual side effects-dry lips. Now 11 years later, I am suffering from a severe anxiety disorder with body dimorph

<b>Describe Your Tazocin Experience Here:</b>after it was administered to my farther in hospital for the first time on day he was due to be released he had a cardiac arrest with multiple organ failure and subsequently died

Endosulfan can causes genetic disorder,body disability, impotency in Male & Female both.. So be careful say no to Endosulfan & other pesticides

I took Champix in March of '08 and I am still suffering from most of the side effects of this poisonous drug. To name a few Psychosis NOS, Major Depressive Disorder, suicidal, Emotional instability, agression, rage, Somatoform Di

I was diagnosed with hypothyroidism about 2 years ago. I have been prescribed just about every brand of medication for my disorder and have never successfully gotten my symptoms under control, even with some of the more

<span style='color: #808080;'><b>Describe Your Schizophrenia from HPV (GARDASIL) 2007 Experience Here:My 15 year old sonjust received first vaccination for HPV, nine days later experienced a psychotic disorder for one week, now

<span style='font-weight: bold;'><a href='' rel='nofollow'>cardiac disorder</a>, <a href='' r

Abilify for BiPolar Disorder, how does it work for you?

Cardiac Disorder Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Condition: Diabetes Mellitus Type 2
Interventions: Drug: Vildagliptin followed by Sitagliptin;   Drug: Sitagliptin followed by Vildagliptin
Outcome Measures: The hypoglycemic profile of vildagliptin compared to sitagliptin;   Number of hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment.;   Duration of hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment;   grade of severity of hypoglycemia;   Number of severe hypoglycemic events during vildagliptin treatment compared to sitagliptin treatment;   Glucose fluctuations during the day under vildagliptin treatment compared to sitagliptin treatment;   Impact of hypoglycemic events on ECG abnormalities;   Status of pro-inflammatory biomarkers under vildagliptin treatment compared to sitagliptin treatment;   Pro-insulin/C-Peptide ratio during vildagliptin treatment compared to sitagliptin treatment.
2 Recruiting Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
Conditions: Type 1 Diabetes;   Insulin Dependent Diabetes;   Juvenile Onset Diabetes Mellitus;   Autoimmune Diabetes
Intervention: Drug: Vildagliptin
Outcome Measures: Beta cell function;   Immune and inflammatory profile;   Secretion of Glucagon and GLP-1;   Glycemic variability
3 Not yet recruiting Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women
Conditions: 1- Microvascular Function;   2-oxidative Stress;   3-inflammation
Intervention: Drug: Vildagliptin
Outcome Measures: Change from Baseline in microcirculation function at 30 days;   Change from Baseline in endothelial function at 30 days
4 Recruiting Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin
Condition: Type 2 Diabetes
Interventions: Drug: Vildagliptin;   Drug: Placebo
Outcome Measures: Proportion of patients responding to treatment (HbA1c less than 7%);   Compare HbA1c and other clinical and laboratory parameters (fasting plasma glucose (FPG), fasting lipids, weight)
5 Recruiting Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension
Conditions: Type 2 Diabetes Mellitus;   Hypertension;   Endothelial Dysfunction
Interventions: Drug: Glibenclamide;   Drug: Vildagliptin
Outcome Measures: Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment;   Change from baseline in the central blood pressure after 12 weeks of vildagliptin x glibenclamide treatment
6 Recruiting Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin;   Drug: Vildagliptin;   Drug: Saxagliptin
Outcome Measures: Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 12;   Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12;   Change From Baseline in 2-hour Postprandial Glucose at Week 12;   Change From Baseline in Fasting Insulin at Week 12;   Change From Baseline in Fasting Glucagon at Week 12;   Change From Baseline in 2-hour Postprandial Insulin at Week 12;   Change From Baseline in 2-hour Postprandial Glucagon at Week 12;   Change From Baseline in 2-hour Postprandial Glucagon-like Peptide-1 (GLP-1) at Week 12;   Change From Baseline in Body Weight at Week 12;   Change From Baseline in Fasting Plasma Lipids at Week 12;   The Proportion of Patients Achieving A1C < 7% and Achieving A1C<6.5% at Week12
7 Recruiting VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo to vildagliptin;   Drug: vildagliptin;   Drug: Metformin
Outcome Measures: Rate of loss in glycemic control over time;   Time to initial treatment failure;   Rate of loss in glycemic control in fasting plasma glucose;   Rate of loss in glycemic control in fasting plasma glucose (FPG) during period 2;   Rate of loss of beta cell function from baseline to end of study ( 5 years);   Number patients with adverse events, death and serious adverse events;   Rate of loss in glycemic control in over time;   Rate of change in insulin sensitivity from baseline to end of study (5 years)
8 Recruiting Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Vildagliptin
Outcome Measures: Change from baseline in glycosylated hemoglobin (HbA1c) at week 24;   Change from baseline in glycosylated hemoglobin (HbA1c) at week 12;   Change from baseline in fasting plasma glucose(FPG) at week 12 and 24;   Change from baseline in postprandial plasma glucose(PPG) at week 12 and 24;   Change from baseline in mean amplitude of glycemic excursions (MAGE) by 72-hour continuous glucose monitoring system (CGMS) after 24-week;   Percentage of patients reaching the glycemic goal at week 12 and 24;   Number of patients with adverse events, serious adverse events and hypoglycemic events
9 Recruiting Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
Condition: Type-2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Metformin
Outcome Measures: Mean change of HbA1c from Baseline to Month 12;   Mean change in fasting plasma glucose (FPG) from Baseline to Month 12;   Percentage of patients with HbA1c <7.0%;   Percentage of overall drug compliance in 12 months;   Percentage patients with adverse events, serious adverse events and death as an assessment of overall safety and tolerability
10 Unknown  Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).
Condition: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
Intervention: Drug: Vildagliptin
Outcome Measures: Endothelial Function;   Number and Function of Progenitor Cells
11 Recruiting Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: Vildagliptin;   Drug: Metformin;   Drug: sulfonylurea (SU);   Drug: Basal Insulin
Outcome Measures: Percentage of patients who reported at least one symptomatic hypoglycemic event during the 24 week randomized period in both treatment arms;   Percentage of patients reaching their glycemic target without hypoglycemic events;   Change from baseline in HbA1c to week 24 in both treatment arms;   Change from baseline in body weight in both treatment arms;   Mean daily insulin dose at Week 24;   Percentage of patients with severe and confirmed hypoglycemic events
12 Unknown  Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Condition: Non-Alcoholic Fatty Liver Disease
Interventions: Drug: Galvus (vitagliptin);   Drug: Galvus + vitamin D
Outcome Measure: decrease in histological findings
13 Recruiting Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Conditions: Type 2 Diabetes;   Hypoglycemia
Interventions: Drug: vildagliptin and metformin (combination);   Drug: glimepiride;   Drug: Metformin
Outcome Measures: glycemic variability measured by Mean Amplitude of Average Glucose Excursions (MAGE);   glycemic variability measured by Continuous Overlapping Net Glycemic Action (CONGA);   Percentage of patients who achieve a decrease equal to or greater than 0.3% in value of HbA1c at week 12 of treatment in comparison to HbA1c value at screening visit;   Percentage of reduction achieved in the mean HbA1c at week 12 of treatment in comparison to HbA1c at screening visit;   Degree of correlation between MAGE value and hypoglycemia incidence;   percentage of patients with incidence of hypoglycemia;   Glycemic variability measured by Total Standard Deviation (TSD);   Number of patients with adverse events, serious adverse events and death
14 Recruiting Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Hypoglycemic Agents;   Diabetic Blood Glucose Monitoring;   Exercise
Interventions: Drug: MET + Vildagliptin Group;   Drug: MET + Glibenclamide Group
Outcome Measures: Change in Glycemic variability;   Change in Hemodynamic response to exercise: Cardiac output (Q), Stroke Volume (SV) and blood pressure (BP)
15 Recruiting Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Insulin;   Drug: Placebo
Outcome Measures: Percentage of patients with hyperglycemic events evaluated with CGM;   Number of hypoglycemia and/or hyperglycemia measured by CGM;   Area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day;   Average of insulin units per day administered during the study;   Changes from the baseline in Lipid Profile;   Change from baseline in Body weight;   Change from baseline in Blood pressure (BP),;   Change from baseline in Fasting plasma glucose (FPG),;   Change from baseline in Hemoglobin A1C (HbA1c);   Change from baseline in Creatinine;   Change from baseline in C-peptide;   Changes from baseline in alanine aminotransferase (ALT)/aspartate aminotransferase (AST);   Changes from baseline in Direct bilirubin;   Changes from baseline in Body Mass Index (BMI);   Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin
16 Recruiting Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: LAF237 50 mg;   Drug: Placebo
Outcome Measures: Change from baseline in glycosylated hemoglobin (HbA1c) at 12 weeks between treatment groups;   Percentage of patients meeting Responder rates in HbA1c;   Change from baseline in Fasting plasma glucose (FPG) at 12 weeks;   Number of participants with hypoglycemia and sever hypoglycemia;   Number of patients with adverse events, serious adverse events and death
17 Unknown  Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Condition: Diabetes Mellitus Type II
Interventions: Drug: Metformin;   Drug: Vildagliptin;   Drug: Glimepiride
Outcome Measures: Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min);   Fasting intact proinsulin levels;   Max postprandial intact proinsulin levels;   Retinal endothelial response to flicker light stimulation;   Mean 24h systolic and diastolic blood pressure;   Erythrocyte deformability;   E-selectin;   Change in body weight;   hsCRP;   HbA1c;   Fasting blood glucose;   Number of hypoglycemic events;   Adverse events;   Drug related adverse events
18 Recruiting Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
Conditions: Type 2 Diabetes Mellitus;   Menopause;   Osteoporosis;   Osteopenia
Interventions: Drug: Vildagliptin;   Drug: Gliclazide MR
Outcome Measures: Markers of bone remodeling;   Bone mineral density of lumbar spine and femur by X-ray absorptiometry;   Glycemic variability;   Calcitonin
19 Recruiting Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
Conditions: Type 2 Diabetes Mellitus;   Ischemic Heart Disease
Interventions: Drug: Metformin plus vildagliptin;   Drug: Metformin only
Outcome Measures: Reduction in serum levels of Interleukin 6 (IL-6);   Improvement in other markers of athero-thrombosis and inflammation:
20 Unknown  The Vascular Effects of Vildagliptin in Insulin Resistant Individuals
Conditions: Insulin Resistance;   Microvascular Disease
Interventions: Drug: Vildagliptin;   Drug: Placebo
Outcome Measures: Capillary pressure;   Macular thickness